NASDAQ:FLXN - Flexion Therapeutics Stock Price, News, Headlines & Rumors

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics Inc (NASDAQ:FLXN) announced its quarterly earnings results on Tuesday, August, 7th. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.22) by $0.06. The specialty pharmaceutical company earned $3.80 million during the quarter, compared to analysts' expectations of $3.96 million. View Flexion Therapeutics' Earnings History.

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Flexion Therapeutics.

9 brokers have issued 12-month price targets for Flexion Therapeutics' shares. Their predictions range from $36.00 to $570.00. On average, they anticipate Flexion Therapeutics' stock price to reach $98.8889 in the next twelve months. This suggests a possible upside of 353.8% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

Flexion Therapeutics saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 10,518,815 shares, a decline of 3.7% from the July 13th total of 10,922,687 shares. Based on an average trading volume of 387,639 shares, the short-interest ratio is presently 27.1 days. Currently, 33.3% of the company's stock are short sold. View Flexion Therapeutics' Current Options Chain.

Some companies that are related to Flexion Therapeutics include Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN) and Global Blood Therapeutics (GBT).

Media stories about FLXN stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Flexion Therapeutics earned a media and rumor sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 46.45 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Flexion Therapeutics.

Flexion Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (9.17%), BlackRock Inc. (7.52%), Peregrine Capital Management LLC (1.77%), Wasatch Advisors Inc. (1.72%), Ardsley Advisory Partners (1.57%) and Artisan Partners Limited Partnership (1.44%). Company insiders that own Flexion Therapeutics stock include David Arkowitz, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Raymond James & Associates, BB&T Securities LLC, Alps Advisors Inc., Alps Advisors Inc., Raymond James Financial Services Advisors Inc. and Berson & Corrado Investment Advisors LLC. View Insider Buying and Selling for Flexion Therapeutics.

FLXN stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Zweig DiMenna Associates LLC, BlackRock Inc., Clearline Capital LP, Ardsley Advisory Partners, Bank of America Corp DE, Gagnon Securities LLC and Mutual of America Capital Management LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include David Arkowitz, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $21.79.

Flexion Therapeutics has a market capitalization of $868.25 million and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]